Unique ID issued by UMIN | UMIN000002330 |
---|---|
Receipt number | R000002849 |
Scientific Title | Japanease multi-center clinical trial to assess the inhibitory effects of branched chain amino acids on the recurrence after curative treatment of hepatocellular carcinoma |
Date of disclosure of the study information | 2009/08/12 |
Last modified on | 2012/02/15 19:43:25 |
Japanease multi-center clinical trial to assess the inhibitory effects of branched chain amino acids on the recurrence after curative treatment of hepatocellular carcinoma
HCC prevention study by BCAA
Japanease multi-center clinical trial to assess the inhibitory effects of branched chain amino acids on the recurrence after curative treatment of hepatocellular carcinoma
HCC prevention study by BCAA
Japan |
Hepatocellular carcinoma
Medicine in general | Hepato-biliary-pancreatic medicine |
Malignancy
NO
To assess the inhibitory effects of branched chain amino acids on the recurrence after curative treatment of hepatocellular carcinoma
Efficacy
Confirmatory
Pragmatic
Not applicable
Time to recurrence of hepatocellular carcinoma
Survival time,
Change of hepatic reserve,
Change of lipid metabolisum and glucose tolerance,
Change of nutritional state, etc
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
YES
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Medicine |
Diet therapy group
Diet + BCAA therapy group
20 | years-old | <= |
Not applicable |
Male and Female
The following HCC patients who are curatively treated with resection or RFA.
1.20 years of age and older.
2.HCV RNA positive liver cirrhosis and 2.8-4.0 g/dl in serum albumin level.
3.New-onset HCC (no extrahepatic lesion, no more than 3lesions and the largest measuring 3cm and below).
4.Clinical diagnosis with imaging tests and tumor markers, add to pathological findings in impossible cases.
5.Comfirmation of no recurrence with CE-CT or CE-US, MRI at a month after treatment.
1.Impregnated patient
2.Complication of ascites, edema and hepatic coma
3.Intrahepatic cholangiocarcinoma and metastatic liver tumor
4.Patient who is difficult to keep a diet therapy going
5.Insulin-treated diabetic patient
6.HCV negative patient after interferon therapy
7.HBsAg positive patient, heavy user of alcohol (more than 60g/day/ ethanol)
8.Patient who is in treatment with antiviral drug (Interferon, Peg-interforon, Ribavirin, etc)
9.Patient who is complicated with renal dysfunction including dialysis.
10.Patient who is associated with heavy heart, lung and hematological disorder, or others.
11.Inegible patient at a physician's discretion
200
1st name | |
Middle name | |
Last name | Kazuyuki Suzuki |
Iwate Medical University, School of Medicine
Division of Gastroenterology and Hepatology, Department of Internal Medicine
Uchimaru, Morioka, Iwate, 020-8505, Japan
1st name | |
Middle name | |
Last name |
Iwate Medical University, School of Medicine
Division of Gastroenterology and Hepatology,Department of Internal Medicine
Uchimaru, Morioka, Iwate, 020-8505, Japan
Ministry of Health, Labour and Welfare
Research grant from tha Japanease Ministry of health, Labour and Walfare
Japan
NO
2009 | Year | 08 | Month | 12 | Day |
Unpublished
Terminated
2009 | Year | 03 | Month | 21 | Day |
2009 | Year | 08 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2009 | Year | 08 | Month | 12 | Day |
2012 | Year | 02 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002849